Skip to main content
Fig. 2 | BMC Gastroenterology

Fig. 2

From: Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment

Fig. 2

Comparison of induction of clinical remission among second-line drugs. There were no significant differences in clinical remission rates between the vedolizumab and tofacitinib groups in UC patients (p = 0.509) or between the vedolizumab and ustekinumab groups in CD patients (p = 0.820) at week 16 after the initiation of induction therapy. UC, ulcerative colitis; CD, Crohn’s disease

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us